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FLETCHER ET aL. false positive rate averages approximately 15%.3 Hence, it is difficult to ascertain whether an individual is infected with HCV based on screening-test-positive results. This undermines the reliability of these assays in routine diagnostic settings.
In India, automated chemiluminescence immunoassay (CLIA) analyzers are increasingly being used in high volume laboratories.
Considering several advantages of CLIA, many laboratories use this as the first line assay to screen for anti-HCV. 6, 7 In our assessment thus far, Architect anti-HCV assay generates many repeatedly reactive low signal-to-cut-off (S/Co) ratio results compared to ortho which is an enzyme immunoassay (EIA). Both are FDA-approved anti-HCV screening assays. Currently Centres for Disease Control (CDC) recommends the use of FDA approved assay for initial testing of HCV antibody without emphasizing on the importance of S/Co ratio and HCV-PCR to identify current HCV infection. 8 However, the earlier CDC guidelines was remarkably different which emphasized on certain S/Co ratios of anti-HCV assays to predict reliably the true antibody positive results regardless of the anti-HCV prevalence. 3, 9 This strategy was adopted earlier
by CDC for judicious use of expensive reflex supplemental testing. 3 In contrast, United Kingdom Health Protection Agency (UK HPA) has suggested a second EIA as an alternative for confirmation of HCV antibody in routine clinical laboratory. 10 This study was undertaken to identify the reliability of Architect anti-HCV assay and to evaluate the agreement of this assay with Ortho, Tri-dot assay and HCV-PCR. Using Latent Class Analysis (LCA), we have also attempted to establish the accuracy indices of these assays in the absence of gold standard for comparison.
| METHODS

| Samples
A total of 78 788 consecutive sera were screened routinely for anti-HCV in the Department of Clinical virology, Christian Medical College, Vellore, India. This study was approved by ethics committee. All sera were stored at 4°C for anti-HCV testing and at −60°C for HCV PCR testing. 
| Anti
| HCV-PCR
Abbott RealTime HCV (Abbott Molecular Inc., Des Plaines, IL, USA) is an in vitro RT-PCR assay for the quantification of HCV RNA. It works on TaqMan principle, the amount of target sequence at each amplification cycle is measured by fluorescent-labeled oligonucleotide probes.
The cycle at which the amplification is detected by the m2000rt is proportional to the log of the HCV concentration of the sample.
| Laboratory testing
All sera were prospectively tested in i2000SR using Architect anti-HCV assay. Sera that were negative (S/CO<1.0) were considered negative for anti-HCV. One thousand and twenty-four sera that were initially reactive were retested in duplicate according to manufacturer's guide- 
| Statistical analysis
The concordance between pairs of assays and all three screening assays were calculated. Agreement between pairs of assays was calculated using Kappa statistics. LCA was performed for all three assays to determine the diagnostic accuracy measures for the respective assays. The distribution of S/Co ratios for anti-HCV screening assays was compared with HCV PCR results using medians with interquartile range (IQR) by Mann-Whitney U test. A P-value of <.05 was considered statistically significant. Receiver operating characteristic (ROC)
curve was plotted to determine the optimal cut-offs for S/Co ratios in diagnosing HCV infection. All statistical analysis was performed using STATA 11.0 (StataCorp, College Station, TX, USA).
| RESULTS
| Concordance and level of agreement
Architect HCV reactive (n=1000) and additional non-reactive sera (n=300) were compared with Ortho HCV and HCV Tri-dot assays. The concordance rate for sera that were reactive in Architect HCV was 29.8% for all three assays, 31.2% for Architect HCV and HCV Tri-dot and 45.2% for Architect HCV and Ortho HCV. We found higher concordance rate (80.7%) between Ortho HCV and HCV Tri-dot assay.
Irrespective of the assay, the concordance rate for negative sera (n=300) that were initially anti-HCV negative in Architect HCV was 99.7%. The level of agreement as assessed by kappa is shown in Table 1 .
| Latent class analysis
LCA revealed that the sensitivity and specificity were 100% and 36.1% for Architect HCV, 93.8% and 100% for Ortho HCV and 63.8%
and 100% for HCV Tri-dot respectively (data not shown).
| Receiver operating characteristic curve analysis
ROC-curve analyzes were performed for Ortho HCV and HCV Tri-dot assays to determine optimal S/Co ratios of Architect HCV for the prediction of anti-HCV positive results in two screening assays. When
Architect HCV was compared with Ortho HCV, the maximum diagnostic sensitivity (82.3%) and specificity (82.3%) was observed at
Architect HCV S/Co ratio of 2.78 (data not shown). Similarly, when
Architect HCV was compared with HCV Tri-dot assay, the maximum diagnostic sensitivity (90.6%) and specificity (91.2%) was seen at S/Co ratio of 4.7 (data not shown). When this analysis was performed for HCV-PCR testing, an optimal S/Co ratio of 6.28 predicted the viremic status with the diagnostic sensitivity and sensitivity of 94% and 91.1%
respectively (Figure 1 ).
| Estimation of accuracy indices
Accuracy indices including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were estimated for Architect HCV at various S/Co ratios by comparing with Ortho HCV and HCV Tri-dot assays. Architect HCV S/Co ratio of >8 showed higher accuracy indices in both the assays to reliably diagnose HCV infection (Tables 2, 3 ). We also found that 39.8% of the sera were positive by Architect HCV and HCV-PCR (data not shown).
| HCV antibody levels and viremia
The Architect median S/Co ratio was 1.93 (IQR 1.39-3.03) for PCRnegative sera and the median S/Co ratio was 13.20 (IQR 11.41-14.40)
for PCR-positive sera (P<.0001, Figure 2 ). The Ortho HCV median S/Co ratio was 0.45 (IQR 0.05-2.18) for PCR-negative sera and the median S/Co ratio was 6.63 (IQR 6.60-6.64) for PCR-positive sera (P<.0001, Figure 3 ).
| DISCUSSION
Accurate diagnosis of HCV infection is a key for effective management of HCV infection. To achieve this, several screening assays with various principles are routinely used. 11 HCV screening assays are known to generate high rate of false positive results. 12 Resolving false positive results is one of the critical challenges of HCV diagnosis. In our experience, Architect generated lot of repeatedly reactive low S/Co ratio results among low risk individuals. In our tertiary care setting, samples are received from patients with assorted risk groups often without adequate clinical information to aid HCV diagnosis.
In such circumstances, it is difficult to establish the accuracy of the Architect and HCV-PCR was also inadequate. A recent study independently reaffirmed our findings which showed that significant variations in diagnostic performance exist among anti-HCV assays and false positive results are not infrequent. 13 Apart from variation in assay principle, the poor agreement could be attributed to low S/Co ratio (<5.0) in Architect. 9 Furthermore Ortho and Tri-dot use additional NS5
antigens and host organisms for the expression of HCV antigens are also different between Architect and Ortho assays. We speculate that these factors could have contributed to the variation in diagnostic performance of anti-HCV assays.
Since there is no gold standard assay available for comparison, LCA was performed to find out the accuracy indices of three anti-HCV assays. The sensitivity was highest for the Architect and the specificity was highest for Ortho and Tri-dot. Based on these analyses, Architect could be used as a screening assay and Ortho can be used as a second assay for distinguishing true positivity from biologic false positivity.
And Tri-dot assay can play a similar role in diagnosis of HCV infection which should be judiciously used in resource poor settings. Good agreement between Ortho and Tri-dot in the present study reaffirms our previous study findings. 14 Furthermore, the specificity of Architect was 36.1% indicating false positivity associated with this assay. Kesli et al. 15 had also shown that the specificity of Architect HCV was 26.9% which independently validates our finding. Hence, it is important to test sera repeatedly reactive in Architect in second EIA to obtain reliable anti-HCV results.
ROC curve analyses were performed to determine a specific Architect S/Co ratio that would predict maximum sensitivity and specificity in Ortho, Tri-dot and HCV-PCR. The Architect was compared with Ortho on the premise that the currently available Ortho assays are known to have exquisite specificity. 16 At Architect HCV S/Co ratio of ≥2.78, Ortho HCV showed maximum diagnostic sensitivity and specificity. Furthermore, this comparison was extended to HCV Tridot assay because this assay was comparable to Ortho HCV in anti-HCV diagnosis in our setting. categorized and accuracy indices were estimated to establish optimal S/Co ratio that could predict the anti-HCV positive result in Ortho HCV and HCV Tri-dot assays. The Architect S/Co of >8 showed highest sensitivity, specificity, PPV, and NPV for both assays. This S/Co ratio is higher than S/Co ratio established by CDC which was ≥5.0 for Architect. 3, 9 A similar S/Co ratio (≥5.0) was also shown in the Chinese Population. 17 Therefore, further studies are warranted to establish the S/Co ratio to identify true anti-HCV positive result in Architect.
In conclusion, Architect anti-HCV is a highly sensitive screening assay, however false positive results are not infrequent. Thus, S/Co ratio of ≥1 to <8 in Architect requires HCV-PCR to identify current HCV infection for timely management and or EIA to distinguish true positivity from false biologic positivity.
